All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Rena BucksteinDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto, CA. We asked, How can we tailor treatment to improve outcome in MDS?
How can we tailor treatment to improve outcome in MDS?
In this video, Buckstein outlines outcomes that could be improved by tailored treatment, such as overall survival, leukemia-free survival, and quality of life. She talks about the importance of next-generation sequencing in identifying mutations and clarifying diagnosis and prognosis, as well as permitting personalization of therapy. Buckstein goes on to discuss ongoing studies and promising treatments available for patients with MDS.